Catalyst Pharmaceuticals Q2 2023 Earnings Report $21.63 -0.42 (-1.92%) As of 02/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Catalyst Pharmaceuticals EPS ResultsActual EPS$0.33Consensus EPS $0.25Beat/MissBeat by +$0.08One Year Ago EPSN/ACatalyst Pharmaceuticals Revenue ResultsActual Revenue$99.58 millionExpected Revenue$92.77 millionBeat/MissBeat by +$6.81 millionYoY Revenue GrowthN/ACatalyst Pharmaceuticals Announcement DetailsQuarterQ2 2023Date8/9/2023TimeN/AConference Call ResourcesPress ReleaseCPRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Catalyst Pharmaceuticals Earnings HeadlinesThose who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374%February 17, 2025 | finance.yahoo.comCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025February 12, 2025 | globenewswire.comYour trading day could end at 11 AMWhat do you usually do between 9:35 AM and 11:00 AM? Catch up on emails? Attend a meeting? Maybe grab a coffee? For me, it's become the most important part of my trading day. 85 minutes. That's usually all it takes. Set up at 9:35 AM… Check back at 11:00 AM. And when things work out, there's an extra $100 to $150 in my account… on a $1000 starting stake. Sounds too simple, doesn't it?February 22, 2025 | ProsperityPub (Ad)Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform RecommendationFebruary 5, 2025 | msn.comBaird starts Catalyst Pharma with Outperform, $28 targetFebruary 4, 2025 | msn.comCatalyst Pharmaceuticals initiated with an Outperform at BairdFebruary 4, 2025 | markets.businessinsider.comSee More Catalyst Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email. Email Address About Catalyst PharmaceuticalsCatalyst Pharmaceuticals (NASDAQ:CPRX), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.View Catalyst Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
